Ledger. Australian venture funding, tracked

Gastroenterologist, U of Adelaide, Glyscend, Inc.

Chris Rayner

Coverage

Stories naming Chris Rayner. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Series A US$20.5m

Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Glyscend has begun a Phase 1 trial in South Australia for its oral polymer diabetes therapy and presented preclinical data; its US$20.5 million Series A was led by Santé Ventures and Brandon Capital.

Brandon BioCatalyst portfolio 29 Sep 2021 Glyscend, Inc.GlyscendJohns Hopkins UniversityMedical Research Commercialisation FundThiel FoundationBrandon CapitalBreakout LabsSanté VenturesAshish NimgaonkarChris RaynerJill ShumanMichael HorowitzThomas Jozefiak
Series A US$20.5m

Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Glyscend Therapeutics has begun a Phase 1 trial in South Australia of its oral polymer therapy for type 2 diabetes; the piece recalls its US$20.5m Series A led by Santé Ventures and Brandon Capital.

Brandon Capital portfolio 29 Sep 2021 GlyscendJohns Hopkins UniversityMedical Research Commercialisation Fund (MRCF)Thiel FoundationBrandon CapitalBreakout LabsSanté VenturesAshish NimgaonkarChris RaynerJill ShumanMichael HorowitzThomas Jozefiak

Something wrong? Tell us